Brief: Aileron Therapeutics Presents Results From Phase 1 Study In Healthy Volunteers Demonstrating Alrn-6924 Induced Cell Cycle Arrest In Bone Marrow Stem Cells And Hair Follicles At Eortc-Nci-Aacr International Conference

Rein Therapeutics

26/10/2022 11:41

Oct 26 (Reuters) - Aileron Therapeutics Inc  ALRN.O :
    * AILERON THERAPEUTICS PRESENTS RESULTS FROM PHASE 1 STUDY
IN
HEALTHY VOLUNTEERS DEMONSTRATING ALRN-6924 INDUCED CELL CYCLE
ARREST IN BONE MARROW STEM CELLS AND HAIR FOLLICLES AT
EORTC-NCI-AACR INTERNATIONAL CONFERENCE
    * AILERON THERAPEUTICS INC - STUDY SHOWED GREATER DEGREE AND
LONGER DURATION OF EFFECT FOR ALRN-6924 AT HIGHER DOSES
    * AILERON - P53-MEDIATED CELL CYCLE ARREST RESULTS SHOW
POTENTIAL
OF ALRN-6924 TO PREVENT CHEMOTHERAPY-INDUCED NEUTROPENIA,
THROMBOCYTOPENIA, AND ANEMIA
    * AILERON THERAPEUTICS INC - 3-MINUTE IV BOLUS AND 1-HOUR IV
INFUSION DEMONSTRATED SIMILAR SAFETY PROFILES, PHARMACOKINETICS,
AND PHARMACODYNAMICS
    * AILERON THERAPEUTICS INC -  P53-MEDIATED CELL CYCLE ARREST
RESULTS DEMONSTRATE POTENTIAL OF ALRN-6924 TO PREVENT
CHEMOTHERAPY-INDUCED ALOPECIA

Source text for Eikon:  ID:nGNX49SffM 
Further company coverage:  ALRN.O 
 ((Reuters.Briefs@thomsonreuters.com;))